Eytan M. Stein, MD – Leukemia & Early Drug Development Specialist – David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
Eitan M. Stein, MD, Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City, delivered a presentation on the utilization of menin inhibitors in treating acute leukemia. The focus was on their application in patients with KMT2A rearrangements and NPM1 mutations.
Dr. Stein discussed various menin inhibitors and their potency, presenting data that indicated response rates ranging from thirty to fifty percent among patients. He also addressed the issue of resistance, attributing it to point mutations within the binding pocket of menin. The conference showcased insightful discussions featuring eminent investigators and was set against a backdrop of laughter in a picturesque location, leaving attendees enthusiastic about future editions.